MPNs

Ruxolitinib Reduces Spleen Size in Patients With Myelofibrosis and Low-Platelet Counts

July 22, 2020

Ruxolitinib induced clinically meaningful reductions in both spleen size and symptoms for patients with myelofibrosis, including those with low platelet counts.

CPI-0610 Demonstrates Promising Activity as Treatment of Patients with Myelofibrosis

July 20, 2020

In an interview with Targeted Oncology, Srdan Verstovsek, MD, PhD, discussed the data from the MANIFEST trial, which evaluated the use of CPI-0610 as treatment of patients with myelofibrosis.

Evaluating CPI-0610 as Treatment of Patients With Myelofibrosis

July 14, 2020

Srdan Verstovsek, MD, PhD, discusses the potential role of CPI-0610 as treatment of patients with myelofibrosis.

Real-World Survival Outcomes for Elderly Patients With Myelofibrosis Show Correlation With FDA Approval of Ruxolitinib

July 08, 2020

The approval of ruxolitinib may have generated an increased awareness around myelofibrosis, ultimately improving the overall management of this patient population.

Synergy Shown With Navitoclax/Ruxolitinib in JAK2-Resistant Myelofibrosis

July 05, 2020

In an interview with Targeted Oncology, Claire Harrison, MD, FRCP, FRCPath, discussed results from the combination of navitoclax and ruxolitinib, as explored in a phase 2 study.

Managing Patients With Myeloid Malignancies During and After the Global COVID-19 Pandemic

June 24, 2020

During the Virtual 25th Congress of the European Hematology Association (EHA), a group of physicians described their experiences and recommendations for managing patients with myeloid malignancies during the COVID-19 pandemic and after.

Ph-Negative MPNs With Pulmonary Hypertension Associated With Poor Outcomes

June 22, 2020

These data suggest that screening for pulmonary hypertension is warranted in patients with a Philadelphia chromosome-negative myeloproliferative neoplasm, both at the time of diagnosis and during follow-up.

RAS/MAPK Pathway Mutations Show Association With Adverse Survival Outcomes in Myelofibrosis

June 19, 2020

“RASMT associated with adverse phenotypic features were concluded to be an independent predictor of inferior overall survival and were associated with a higher cumulative incidence of leukemic transformation."

Evidence Supports Rechallenging of JAK Inhibitors in Myelofibrosis

June 17, 2020

Naveen Pemmaraju, MD, discusses the clinical implications of a retrospective analysis of 26 patients with myelofibrosis who received benefit from ruxolitinib when it was rechallenged.

Ropeginterferon Provides Improved Hematocrit Control Over Phlebotomy Alone in Low-Risk PV

June 14, 2020

"This interim analysis demonstrated ropeginterferon in low-risk patients is more efficacious in keeping the hematocrit [at target levels]. In addition, we get a better quality of life and the target was reached with a reduction of phlebotomy needs."